These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7989764)

  • 1. An efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4.
    Pericle F; Giovarelli M; Colombo MP; Ferrari G; Musiani P; Modesti A; Cavallo F; Di Pierro F; Novelli F; Forni G
    J Immunol; 1994 Dec; 153(12):5659-73. PubMed ID: 7989764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory.
    Giovarelli M; Musiani P; Modesti A; Dellabona P; Casorati G; Allione A; Consalvo M; Cavallo F; di Pierro F; De Giovanni C
    J Immunol; 1995 Sep; 155(6):3112-23. PubMed ID: 7673726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene.
    Cavallo F; Giovarelli M; Gulino A; Vacca A; Stoppacciaro A; Modesti A; Forni G
    J Immunol; 1992 Dec; 149(11):3627-35. PubMed ID: 1358974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
    Provinciali M; Argentati K; Tibaldi A
    Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes.
    Musiani P; Modesti A; Brunetti M; Modica A; Vitullo P; Gulino A; Bosco MC; Colombo MP; Nanni P; Cavallo F
    Nat Immun; 1994; 13(2-3):93-101. PubMed ID: 8173240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.
    Cavallo F; Martin-Fontecha A; Bellone M; Heltai S; Gatti E; Tornaghi P; Freschi M; Forni G; Dellabona P; Casorati G
    Eur J Immunol; 1995 May; 25(5):1154-62. PubMed ID: 7539748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
    Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
    Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
    Stoppacciaro A; Forni G; Colombo MP
    Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.
    Mortara L; Castellani P; Meazza R; Tosi G; De Lerma Barbaro A; Procopio FA; Comes A; Zardi L; Ferrini S; Accolla RS
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3435-43. PubMed ID: 16740768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha.
    Musiani P; Allione A; Modica A; Lollini PL; Giovarelli M; Cavallo F; Belardelli F; Forni G; Modesti A
    Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
    Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
    Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism.
    Rakhmilevich AL; Janssen K; Hao Z; Sondel PM; Yang NS
    Cancer Gene Ther; 2000 Jun; 7(6):826-38. PubMed ID: 10880012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
    Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
    Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse.
    Takeshita K; Yamasaki T; Akira S; Gantner F; Bacon KB
    Int Immunol; 2004 May; 16(5):685-95. PubMed ID: 15096484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A "stealth effect": adenocarcinoma cells engineered to express TRAIL elude tumor-specific and allogeneic T cell reactions.
    Giovarelli M; Musiani P; Garotta G; Ebner R; Di Carlo E; Kim Y; Cappello P; Rigamonti L; Bernabei P; Novelli F; Modesti A; Coletti A; Ferrie AK; Lollini PL; Ruben S; Salcedo T; Forni G
    J Immunol; 1999 Nov; 163(9):4886-93. PubMed ID: 10528190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma.
    De Giovanni C; Nicoletti G; Landuzzi L; Rossi I; Astolfi A; Ricci C; Di Carlo E; Musiani P; Forni G; Fradelizi D; Nanni P; Lollini PL
    Gene Ther; 2001 Nov; 8(22):1698-704. PubMed ID: 11892837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells.
    Adris S; Chuluyan E; Bravo A; Berenstein M; Klein S; Jasnis M; Carbone C; Chernajovsky Y; Podhajcer OL
    Cancer Res; 2000 Dec; 60(23):6696-703. PubMed ID: 11118055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloantigen-activated lymphocytes from mice bearing a spontaneous "nonimmunogenic" adenocarcinoma inhibit its growth in vivo by recruiting host immunoreactivity.
    Giovarelli M; Santoni A; Forni G
    J Immunol; 1985 Nov; 135(5):3596-603. PubMed ID: 3930610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response.
    Adris S; Klein S; Jasnis M; Chuluyan E; Ledda M; Bravo A; Carbone C; Chernajovsky Y; Podhajcer O
    Gene Ther; 1999 Oct; 6(10):1705-12. PubMed ID: 10516719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.